Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | PAK4 | O96013 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17997478 | 0.82 | PAK4 (0.33) | PAK4 | |
| SCHEMBL5423132 | 0.72 | HTR2A (0.36) | CYP1A2LRRK2HTR2AHTR2CHSD11B1 | |
| SCHEMBL15623924 | 0.72 | GAA (0.41) | CYP1A2LRRK2HTR2AHTR2CHSD11B1 | |
| SCHEMBL14923156 | 0.72 | LRRK2 (0.44) | CYP1A2LRRK2HTR2AHTR2CHSD11B1 | |
| SCHEMBL20050020 | 0.72 | PAK4 (0.34) | PAK4 | |
| SCHEMBL12731902 | 0.72 | — | — | |
| SCHEMBL16178010 | 0.71 | PROKR1 (0.35) | CYP1A2LRRK2HTR2AHTR2CHSD11B1 | |
| SCHEMBL31239647 | 0.71 | LRRK2 (0.37) | CYP1A2LRRK2HTR2AHTR2CHSD11B1 | |
| SCHEMBL21379850 | 0.71 | LRRK2 (0.37) | CYP1A2LRRK2HTR2AHTR2CHSD11B1 | |
| SCHEMBL28177579 | 0.71 | LRRK2 (0.37) | CYP1A2LRRK2HTR2AHTR2CHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | SENDA BIOSCIENCES, INC. (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | AHR, ARNT, AIPL1 | CYP1A2 37/4885LRRK2 2054/4885PAK4 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.